



CIRCULOGENE

Microsatellite Instability (MSI) Biomarker Testing for Multiple Cancers Now Offered Via Blood-based Single Tube

The availability of microsatellite instability (MSI) biomarker testing for all tumor types is advantageous for oncologists and pathologists seeking to identify patients eligible for treatment with pembrolizumab or nivolumab.

The U.S. Food and Drug Administration (FDA) recently granted fast-track approval of Keytruda® (pembrolizumab) for all advanced solid tumors, and Opdivo® (nivolumab) for metastatic colorectal cancer.

MSI,
referred to as
mismatch repair
deficient (dMMR),
results in
1 week

3125 Independence Drive, Suite 301
Birmingham, Alabama 35209

//

The availability of this precise, actionable marker with its quick turnaround time and low cost means patients and their physicians can immediately take advantage of the most recent cancer-fighting therapies."



- Glen Weiss, M.D., M.B.A., medical oncologist and Clinical Associate Professor at University of Arizona College of Medicine-Phoenix

Complete Molecular Testing

CIRCULOGENE is the only company to provide (1) Molecular testing from a single tube of blood for circulating DNA, RNA, MSI as well as hereditary genes; and (2) Molecular testing in tissue for DNA and MSI.

Standard Specimen and Handling

CIRCULOGENE utilizes standard lavender tubes for all blood testing and FFPE for tissue.

Fast Results

1 week for DNA + RNA + MSI + Hereditary

circulogene.com
1.855.614.7083
info@circulogene.com